Study Finds Birth Hypoxia May Increase ADHD Likelihood
January 27, 2026
Brand Name :
N/A
Synonyms :
trebananib
Class :
Limited data available
Data not available
It is an investigational drug, and its status or recommended dosage may change, and it is an angiogenesis inhibitor that targets the angiopoietin axis and was being studied for its potential use in various cancers, including ovarian cancer
Data not available
Refer to adult dosing
the risk of anti-angiogenesis and jaw osteonecrosis may be increased
the risk of methemoglobinemia can be increased
the risk of methemoglobinemia can be increased
the risk of methemoglobinemia can be increased
the risk of methemoglobinemia can be increased
the risk of methemoglobinemia can be increased
the risk of methemoglobinemia can be increased
the risk of methemoglobinemia can be increased
the risk of methemoglobinemia can be increased
the risk of anti-angiogenesis and jaw osteoporosis may be increased
the risk of methemoglobinemia can be increased
the risk of immunosuppression may be increased
the risk of anti-angiogenesis and jaw osteoporosis may be increased
the risk of methemoglobinemia can be increased
the risk of methemoglobinemia can be increased
the risk of methemoglobinemia can be increased
the risk of methemoglobinemia can be increased
the risk of methemoglobinemia can be increased
the risk of methemoglobinemia can be increased
the risk of anti-angiogenesis and jaw osteoporosis may be increased
the risk of anti-angiogenesis and jaw osteoporosis may be increased
Actions and spectrum:
Trebananib is known to inhibit angiogenesis by blocking the interaction between Ang1/Ang2 with the Tie2 receptor
Frequency not defined
Rash
Fatigue
Mucositis
Black Box Warning
None
Contraindication/Caution:
None
Pregnancy consideration:
USFDA pregnancy category: not assigned
Lactation:
The data about the excretion of trebananib into human milk is not known
Pregnancy category:
Pharmacology:
Under investigation
Patient information leaflet
Generic Name: trebananib
Why do we use trebananib?
trebananib is used for fallopian tube cancer, peritoneal cancer, and ovarian cancer. Still this drug is under investigation.